Adding oral selexipag to double oral therapy (DOT) within 6 months significantly reduces the risk of hospitalization and disease progression in patients with pulmonary arterial hypertension (PAH).
Adding oral selexipag to double oral therapy (DOT) within 6 months significantly reduces the risk of hospitalization and disease progression in patients with pulmonary arterial hypertension (PAH).
Machine learning techniques such as combining machine learning with echocardiography and electrocardiography (ECG), show promising results in diagnosing pulmonary arterial hypertension (PAH), offering a potential noninvasive alternative to...
Machine learning techniques such as combining machine learning with echocardiography and electrocardiography (ECG), show promising results in diagnosing pulmonary arterial hypertension (PAH), offering a potential noninvasive alternative to...
A recent study investigated the “sex paradox” in pulmonary arterial hypertension, which highlights better survival outcomes in women despite more severe disease presentation.
A recent study investigated the “sex paradox” in pulmonary arterial hypertension, which highlights better survival outcomes in women despite more severe disease presentation.
Real-world data shows selexipag effectively improves functional class and risk category outcomes in patients with pulmonary arterial hypertension, regardless of maintenance dose.
Real-world data shows selexipag effectively improves functional class and risk category outcomes in patients with pulmonary arterial hypertension, regardless of maintenance dose.
This systematic review explores the impact of cardiovascular and lung comorbidities on pulmonary arterial hypertension patients, revealing the need for tailored management for this high-risk population.
This systematic review explores the impact of cardiovascular and lung comorbidities on pulmonary arterial hypertension patients, revealing the need for tailored management for this high-risk population.
Recent advancements in the treatment of pulmonary arterial hypertension have shifted clinical practices toward combination therapies, particularly highlighting the role of riociguat.
Recent advancements in the treatment of pulmonary arterial hypertension have shifted clinical practices toward combination therapies, particularly highlighting the role of riociguat.
Study findings suggest that a significant proportion of modern idiopathic pulmonary arterial hypertension (IPAH) cases may not exhibit the classic plexiform vasculopathy seen in earlier descriptions of the disease, according to researchers.
Study findings suggest that a significant proportion of modern idiopathic pulmonary arterial hypertension (IPAH) cases may not exhibit the classic plexiform vasculopathy seen in earlier descriptions of the disease, according to researchers.
The pulmonary arterial hypertension drug market is projected to grow to $11.6 billion by 2032, driven by an increase in pulmonary disorders, advancements in treatment options, and greater awareness of the condition.
The pulmonary arterial hypertension drug market is projected to grow to $11.6 billion by 2032, driven by an increase in pulmonary disorders, advancements in treatment options, and greater awareness of the condition.
Patient perspectives play a crucial role in shaping healthcare decisions, and AMCP 2024 session speaker Sarah Emond discusses the importance of patient engagement in drug value assessments within the managed care framework, providing examples...
Patient perspectives play a crucial role in shaping healthcare decisions, and AMCP 2024 session speaker Sarah Emond discusses the importance of patient engagement in drug value assessments within the managed care framework, providing examples...
